A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris

An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris

Open-label cohort study in adult patients with newly diagnosed or relapsing pemphigus vulgaris, with intra-patient dose-adjustment based on clinical response and BTK occupancy, and with conventional immunosuppressive "rescue treatment", if indicated. The duration of therapy in Part A will be 12 weeks, followed by 12 weeks of follow up. The extension phase, Part B includes 24 weeks of therapy, followed by 4 weeks of follow-up.

Study Overview

• Status: Completed
• Conditions: Pemphigus Vulgaris
• Intervention / Treatment: Drug: PRN1008

Detailed Description

Primary Objectives:

To evaluate the safety of PRN1008 in patients with pemphigus vulgaris (PV)

To evaluate the clinical activity of PRN1008 in patients with PV, per criteria in the European Academy of Dermatology and Venereology (EADV) 2014 Pemphigus S2 Guideline (Hertl et al. 2015)

Secondary Objectives

To evaluate the pharmacokinetics (PK) and the pharmacodynamics (PD) of multiple doses of PRN1008 in patients with PV

To evaluate the relationship of PK and PD to each other and to efficacy and safety in this patient population

• Study Type: Interventional
• Enrollment (Actual): 42
• Phase: Phase 2

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Kogarah, New South Wales, Australia, 2217
      • Premier Specialists
  • Victoria
    • East Melbourne, Victoria, Australia, 3002
      • Sinclair Dermatology
    • Melbourne, Victoria, Australia, 3050
      • Royal Melbourne, Dermatology Office
• Croatia
  • Osijek, Croatia, 31000
    • Clinical Hospital Osijek
  • Zagreb, Croatia, 10 000
    • Klinichki Bolnicki Centar Zagreb
• France
  • Rouen, France, 76038
    • Rouen university hospital
  • Siene-Saint Denis
    • Bobigny, Siene-Saint Denis, France, 93009
      • Hopital Avicenne
• Greece
  • Athens, Greece, 16121
    • Hospital of Venereal and Skin Diseases A.Syggros
  • Thessaloniki, Greece, 56429
    • Papageorgiou General Hospital of Thessaloniki
  • Ioannina
    • Ioánnina, Ioannina, Greece, 45500
      • University General Hospital of Ioannina
  • Thessaly
    • Larissa, Thessaly, Greece, 41110
      • University Hospital of Larissa
• Israel
  • Ramat-Gan, Israel, 52621
    • Chaim Sheba Medical Center
  • Tel Aviv, Israel, 64239
    • Tel Aviv Sourasky Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female patients, aged 18 to 80 years old, with biopsy-proven, mild-moderate PV (PDAI 8 to 45) in Part A and mild to severe PV in Part B (PDAI 8 to 60) that are either:

  • newly diagnosed patients (i.e. naïve to an effective induction treatment regimen) for whom an initial period of PRN1008 monotherapy is judged clinically acceptable, or
  • relapsing patients, for whom an initial period of PRN1008 monotherapy, or combination therapy with any of low dose corticosteroid, ie.0.5 mg/kg of prednis(ol)one per day

Exclusion Criteria:

• Pregnant or lactating women
• A history of malignancy of any type, other than surgically excised non-melanoma skin cancers or in situ cervical cancer within 5 years before the day of dosing
• Use of immunologic response modifiers with the following periods prior to Day 1: 1 week: cyclophosphamide; 4 weeks: intravenous immunoglobulin, Kinaret (anakinra) and Enbrel (etanercept); 12 weeks: Remicade (infliximab), Humira (adalimumab), Simponi (golimumab), Orencia (abatacept), Actemra (tocilizumab), Cimzia (certolizumab), Cosentyx (secukinumab), plasmapheresis; 6 months: Rituxan/MabThera (rituximab), ofatumumab, any other anti-CD20 antibody, other long acting biologics
• More than 0.5 mg/kg of prednis(ol)one per day ("low dose corticosteroids") within the two weeks prior to Day 1
• Use of proton pump inhibitor drugs such as omeprazole and esomeprazole
• Has received any investigational drug (or is currently using an investigational device) within the 30 days before receiving the first dose of study medication, or at least 5 times the respective elimination half-life time (whichever is longer)
• History of drug abuse within the precious 12 months
• Alcoholism or excessive alcohol use, defined as regular consumption of more than approximately 3 standard drinks per day
• Refractory nausea and vomiting, malabsorption, external biliary shunt, significant bowel resection that would preclude adequate study drug absorption
• History of anorexia nervosa or periods of three months or more of low body weight in the past 5 years
• Donation of a unit or more of blood or blood products within 4 weeks prior to Day 1
• History of solid organ transplant
• History of epilepsy or other forms of seizures in the last 5 years
• Positive for screening for human immunodeficiency virus, hepatitis B (surface and core antibodies unrelated to vaccination), or hepatitis C (anti-HCV antibody confirmed with Hep C RNA)
• History of active or latent tuberculosis (TB) infection (must test negative using the QuantiFERON test to be eligible)
• History of serious infections requiring intravenous (by catheter that delivers antibiotics into your blood) treatment
• Live vaccine within 28 days prior to baseline or plan to receive one during the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

EXPERIMENTAL: PRN1008; Part A: Open-label PRN1008, 12 weeks; 12 weeks follow-up; Part B: Open-label PRN1008, 24 weeks; 4 weeks follow-up

Drug: PRN1008; Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks. Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks.; Other Names: BTK inhibitor; Rilzabrutinib

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Treatment-emergent Adverse Events	Treatment-emergent adverse events (TEAEs) including clinically significant changes in physical examination, laboratory tests, and vital signs. An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment phase that was defined as the time from the start of study drug up to study completion.	Part A: until 24 weeks and Part B: until 28 weeks
Percentage of Participants Who Are Able to Achieve Control of Disease Activity (CDA) Within 4 Weeks of Starting PRN1008 Treatment Without the Need for Doses of Prednisone or Prednisolone >0.5 mg/kg	CDA was defined as the time at which new lesions cease to form and established lesions begin to heal.	4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Able to Achieve Control of Disease Activity (CDA) Without Corticosteroids Within 4 Weeks	CDA was defined as the time at which new lesions cease to form and established lesions begin to heal.	4 weeks
Percentage of Participants Able to Achieve a Complete Response (CR) Without Corticosteroids	CR was defined as complete healing of all lesions and the absence of new lesions.	Part A: 12 weeks treatment and Part B: 24 weeks treatment
Percentage of Participants Able to Achieve Complete Remission (CR) Without the Need for Doses of Prednisone or Prednisolone of Greater Than 0.5mg/kg	CR was defined as complete healing of all lesions and the absence of new lesions.	Part A: 12 weeks treatment and Part B: 24 weeks treatment
Time to Control of Disease Activity (CDA)	CDA was defined as the time at which new lesions cease to form and established lesions begin to heal. Kaplan-Meier estimate median time is reported.	Part A: until 24 weeks and Part B: until 28 weeks
Time to End of Consolidation Phase (ECP)	ECP was defined as the time at which no new lesions have developed for minimum of 2 weeks, and approximately 80% of existing lesions have healed. The median time to ECP was based on Kaplan-Meier estimate which considered censoring at end of follow-up for patients who didn't have an event. A +/-3 days window for visits at Week 3 and 5, and +/-7 days window for visits at Week 9, 13, 17, 21, 25.	Part A: until 24 weeks and Part B: until 28 weeks
Time to Complete Remission (CR)	CR was defined as complete healing of all lesions and the absence of new lesions.	Part A: until 24 weeks and Part B: until 28 weeks
Time to Relapse After PRN1008 Treatment Discontinuation	Relapse was defined as appearance of ≥3 new lesions/month that do not heal spontaneously within 1 week, or by extension of established lesions, in a patient who has achieved disease control. The median time to relapse was based on Kaplan-Meier estimate which considered censoring at end of follow-up for patients who didn't have an event. A +/-3 days window for visits at Week 3 and 5, and +/-7 days window for visits at Week 9, 13, 17, 21, 25.	Part A: until 24 weeks and Part B: until 28 weeks
Cumulative Corticosteroid Usage	Cumulative corticosteroid usage	Part A: until 24 weeks and Part B: until 28 weeks
Percentage Change From Baseline in Pemphigus Disease Area Index (PDAI) Total Activity Scores	The PDAI questionnaire has 2 components including activity and damage. The activity component consists of skin, scalp and mucosa parts, and the damage component consists of skin and scalp parts. The total activity score was used for the summary of PDAI scores. PDAI total activity score = Total skin activity + Total scalp activity + Total mucosa activity. PDAI Total Activity Score ranged from 0 to 250 points representing disease activity (higher scores mean a worse outcome). Negative change in total activity score from baseline indicates improvement in pemphigus activity.	Part A: until 24 weeks and Part B: until 28 weeks
Change From Baseline in Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) Total Activity Score	ABSIS Total Activity Score ranged from 0 to 206 points representing disease activity (higher scores mean a worse outcome). Negative change in total activity score from baseline indicates improvement in pemphigus activity.	Part A: until 24 weeks and Part B: until 28 weeks
Change From Baseline in Autoimmune Bullous Diseases Quality of Life (ABQOL)	ABQOL score ranged from 0 to 68 points representing disease activity (higher scores mean a worse outcome).	Part A: until 24 weeks and Part B: until 28 weeks
Change From Baseline in Treatment of Autoimmune Bullous Diseases Quality of Life (TABQOL) Scores	TABQOL score ranged from 0 to 68 points representing disease activity (higher scores mean a worse outcome).	Part A: until 24 weeks and Part B: until 28 weeks
Change From Baseline in Appetite (SNAQ Score)	Simplified Nutritional Appetite Questionnaire (SNAQ) score ranged from 0 to 20 points representing disease activity (higher scores mean a better outcome).	Part A: until 24 weeks and Part B: until 28 weeks

Collaborators and Investigators

• Sponsor: Principia Biopharma, a Sanofi Company
• Collaborators: Principia Biopharma Australia Pty Ltd.

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 22, 2016
• Primary Completion (ACTUAL): December 18, 2019
• Study Completion (ACTUAL): January 10, 2020

Study Registration Dates

• First Submitted: February 24, 2016
• First Submitted That Met QC Criteria: March 4, 2016
• First Posted (ESTIMATE): March 10, 2016

Study Record Updates

• Last Update Posted (ACTUAL): February 13, 2023
• Last Update Submitted That Met QC Criteria: January 18, 2023
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Immune System Diseases; Autoimmune Diseases; Skin Diseases, Vesiculobullous; Pemphigus
• Other Study ID Numbers: PRN1008-005; 2015-003564-37 (EUDRACT_NUMBER)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• product manufactured in and exported from the U.S.: Yes